ETFs Gilead Sciences, Inc.

Equities

GILD

US3755581036

Pharmaceuticals

Market Closed - Nasdaq 21:00:00 12/07/2024 BST 5-day change 1st Jan Change
69.96 USD -0.01% Intraday chart for Gilead Sciences, Inc. +4.90% -13.64%

ETFs positioned on Gilead Sciences, Inc.

Name Weight AuM 1st Jan change Investor Rating
0.35% 36 M€ +4.49% -
0.35% 322 M€ -.--% -
0.35% 29 M€ -.--% -
0.34% 1,848 M€ -.--% -
0.34% 559 M€ -.--% -
0.34% 6 M€ +17.98% -
0.33% 133 M€ +12.78% -
0.32% 18 M€ +5.45% -
0.32% 26 M€ +32.03% -
0.29% 825 M€ +15.37%
0.29% 9 M€ +12.65% -
0.28% 38 M€ -.--%
0.27% 1 M€ -.--%
0.26% 7 M€ +0.11% -
0.25% 55 M€ +17.57%
0.25% 261 M€ -.--% -
0.25% 200 M€ +15.37% -
0.25% 35 M€ +18.75% -
0.25% 488 M€ +18.43%
0.25% 205 M€ -.--%
0.24% 20 M€ +2.37% -
0.23% 61 M€ +31.33% -
0.21% 35 M€ +16.10% -
Gilead Sciences, Inc. specializes in the development, manufacturing and marketing of therapeutic products. Net sales break down by source of income as follows: - sale of drugs (98.9%): for the treatment of HIV (63% of net sales), COVID-19 (20.4%), hepatitis C virus (6.6%), hepatitis B virus (3.6%) and other (6.4%; primarily cytomegalovirus retinitis, and advanced Kaposi sarcoma resulting from HIV); - other (1.1%): especially royalties and revenue from research and development services and from subcontracted production of therapeutic products. Net sales are distributed geographically as follows: the United States (69.2%), Europe (16.4%) and other (14.4%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B-
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
31
Last Close Price
69.96 USD
Average target price
83.08 USD
Spread / Average Target
+18.75%
Consensus
  1. Stock Market
  2. Equities
  3. GILD Stock
  4. ETFs Gilead Sciences, Inc.